... [(11)C]choline PET/ CT in prostate cancer patients with biochemical recurrence after radical prostatectomy World J Urol 2009, 27:619-625 Hara T, Kosaka N, Kishi H: PETimaging of prostate cancer using ... tumor characteristics Pt Age (yr) stage Gleason iPSA PSA nadir dt PSA (mo.) PSA before FEC PET/ CT Previous therpay 73 cT2 cN0 11,5 - 11,5 pos (P) - 59 cT2 cN0 9,1 - 9,1 pos (P) - 64 cT3 cN0 n.a ... Figure SUVmax for primary and recurrent prostate cancer The maximum standardized uptake value (SUVmax) is given for primary and recurrent prostate cancer receiving a Choline -PET/ CTfor diagnosis...
... considered for the mismatch analysis: - the volume identified by PET but not by CT (PEToutCT), - the volume identified by CT but not by PET (CToutPET), - the common volume of CT and PET (CT &PET) Results ... rank test showed PET- GTV and PET- CTV to be significantly smaller than CT- GTV (p = 1.2 × 10-4) and CT- CTV (p = 2.9 × 10-4) respectively PET/ CT- GTV and PET/ CT- CTV, that were used for clinical purposes, ... tract tumors In particular, the GTV was drawn manually on CT and semi-automatically on PET images For delineating the PET/ CT- GTV and the PET/ CT- CTV, the operator considered both CT and PET information...
... were contoured on CT images obtaining CT- GTV, PET (PET- GTV), and PET/ CT images (PET/ CTGTV) The PET/ CT- GTV included both PET and CT information The clinical target volume (CTV), for treatment purpose, ... volume identified by PET but not by CT; "CToutPET" is the volume identified by CT but not by PET; "CT &PET" is the common volume of PET and CT Results Tumor staging PET/ CTimaging lead to a change ... PET/ CT- GTV PEToutCT CToutPET CT &PET 26.0 5.5 8.1 11.2 5.0–78.7 0.0–21.2 0.7–28.0 0.4–36.2 15.9–36.2 2.4–8.7 4.4–11.8 6.2–16.2 Abbreviations: PET/ CT- GTV: the composite volume between PET and CT; ...
... Screening forbreastcancer Available at: http://www.who.int /cancer/ detection/breastcancer/en/index.html Canadian Task Force on Preventive Health Care Breast self-examination to screen forbreastcancer ... Corrected for lead time vs predicted Florence 3.20% 1.40% Corrected for lead time vs predicted Italy 50-54 7.40% NR NR Corrected for lead time vs predicted 55-59 -0.60% NR NR Corrected for lead ... preexisting breastcancer and not considered at high risk forbreastcancer based on extensive family history of breast or ovarian cancer or other personal risk factors, such as abnormal breast pathology...
... disease and cancer It therefore no longer seems reasonable to attend forbreastcancer screening In fact, by avoiding going to screening, a woman will lower her risk of getting a breastcancer diagnosis ... treatment forbreastcancer in Norway: comparative analysis of cancer registry data BMJ 2011;343:d4692 20 NHS cancer screening programmes BASO Breast Audit 1999/2000 www.cancerscreening.nhs.uk/breastscreen/publications.html ... dying from breastcancer (see Documentation for the facts and figures below) Screening does not reduce the overall risk of dying, or the overall risk of dying from cancer (including breast cancer) ...
... docetaxel-loaded nanoparticles based on poly(lactideco-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies ... PA, USA) The sections were collected on 200-mesh copper grids and put into the TEM forimaging on a Gatan digital camera Powder X-ray diffraction pattern analysis Powder X-ray diffraction [PXRD] ... cytotoxicity on the SUM 225 breastcancer cell line by dynamic light scattering, high performance liquid chromatography, electron microscopies, powder X-ray diffraction, and lactate dehydrogenase bioassay...
... multidrug resistance in human breastcancer cells and therefore have considerable potential for treatment of breastcancer Acknowledgments The authors are grateful for financial support from the ... mechanism of docetaxel resistance in breastcancer cells BreastCancer Res 6(5), R601–R607 (2004) G Reich, In vitro stability of poly (D, L-lactide) and poly (D, L-lactide)/poloxamer nanoparticles ... interact with multidrug-resistant (MDR) tumors resulting in drastic sensitization of these tumors with respect to various anticancer agents [13, 14] The key attribute for the biological activity...
... Differentiation Figure A schematic summary of breastcancer heterogeneity According to the cancer stem cell hypothesis, breastcancer is driven by a limited number of cancer- initiating cells The progeny ... SNPs are differen tially expressed in the breastcancer subtypes BreastCancer Res 2007, 9:113 Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options Lancet Oncol ... high-throughput molecular analyses have provided unprecedented tools for dissecting and understanding cancer heterogeneity Five subtypes of breastcancer were initially proposed: luminal A and luminal B (both...
... Seroma formation following breastcancer surgery Breast J 2003, 5:385-8 Woodworth PA, McBoyle MF, Helmer SD, Beamer RL: Seroma formation after breastcancer surgery: incidence and predicting factors ... mastectomy Am J Surg 1998, 176:8-14 Unalp HR, Onal MA: Analysis of risk factors affecting the development of seromas following breastcancer surgeries: seromas following breastcancer surgeries Breast ... seroma formation after mastectomy and axillary dissection: a pilot study Int J Clin Pract 2006, 60:562-564 Porter K, O’Connor S, Rimm E, Lopez M: Electrocautery as a factor in seroma formation...
... localized estrogen receptors in human breastcancerCancer Res 1990, 5012:3545-3550 British Breast Group: Assessment of response to treatment in advanced breastcancer Lancet 1974, 2:38-39 Hayward ... Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in BreastCancer Clinical Cancer Research 2005, 112:865s-870s Legault-Poisson ... response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer 1977, 393:1289-1294 Simon...
... tamoxifen for prevention of breastcancer Br J Cancer 1989, 60(1):126-31 Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM: Endometrial cancer in tamoxifen-treated breastcancer ... tamoxifen forbreastcancer is just a random observation and there is no relationship between them As mentioned earlier, the granulosa cell tumors in conjunction with tamoxifen administration forbreast ... 33(4):445-8 Early BreastCancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials Lancet 1998, 351:1451-1467 Cuzick J, Powles T, Veronesi U, Forbes...
... predictive factor forbreastcancer at surgical excision in patients with diagnosed ADH at CNB Consistent with our findings, Ko et al [18] observed an increase in underestimation rates in subjects ... Dupont WD, Page DL: Risk factors forbreastcancer in women with proliferative breast disease New England Journal of Medicine, The 1985, 312:146-151 Rosen PP: Proliferative breast "disease" An unresolved ... results Conclusion Only age at the time of biopsy ( 50 years) is an independent predictive factor forbreastcancer at surgical excision in patients with diagnosed ADH at CNB Identification of...
... assigned to receive 45 Gy to the whole breast, BED was 55 Gy for early effects, 78 Gy for late effects versus 60 Gy for early effects, 83 Gy for late effects in the group treated with 50 Gy Sequential ... R, Darby S, Early BreastCancer Trialists’ Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breastcancer on local recurrence and 15-year ... correction for tissue heterogeneity For each patient, dosevolume histograms (DVHs) for target, lung and left ventricle for left-sided cancers were calculated The same technique had been used for...
... dose-response relationship forbreastcancer was derived based on the analysis of breastcancer induction after Hodgkin’s disease, a cancer risk model developed for high doses including fractionation based ... relationship forbreastcancer induction based on the analysis of Hodgkin’s disease patients by Travis et al [8] and breastcancer induction from the A-bomb survivors [11] A recently developed cancer ... of model parameters for a dose-response relationship forbreastcancer covering dose levels relevant for radiotherapy In addition a model for the age dependence of breastcancer risk was verified...
... prostate apex Nevertheless, CT scan is still widely used for prostate cancer planning, being the standard imaging technique for most radiotherapy Institutes where access to MRI for planning is still ... Incrocci L: Changes in sexual function after treatment of male cancer JMHG 2005, 2:236-243 Incrocci L: Erectile dysfunction and radiation therapy for prostate cancer Sexologies 2006, 15:116-120 ... 3D conformal radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 1996, 35:869-874 Crook J, Esche B, Futter N: Effect of pelvic radiotherapy for prostate cancer...
... before and after therapy was performed by independent PET and CT readers PET and CT images were also merged (fusion analysis) for functional and anatomic correlation CT -PET images were displayed on ... F-18 FDG PETCT and post-treatment PET- CT were included Baseline pre-radiotherapy PET- CT was performed before any treatment, followed by post-radiotherapy PET- CT at a median of seventy-one days ... follow-up Discussion Combined PET- CT is now gradually replacing single modality PET scan for diagnostic and staging evaluation of lung cancers PET- CT is emerging as a tool for radiation treatment planning...
... selective delivery forbreastcancer treatment Bioconjug Chem 2009, 20:2247-2253 14 Ma G, Yang J, Zhang L, Song C: Effective antitumor activity of paclitaxelloaded poly (varepsilon-caprolactone)/pluronic ... MCF-10A breast normal cell line was noted than in the 4T1 and MCF-7 breastcancer cell lines Nonetheless, the Magh-Rh (H cit) and Lip-Magh-Rh (H cit) treatments were more selective to breastcancer ... actin alterations MCF-7 cells without treatment (control) showed organized spread actin in the cytoplasm and interactions between surrounding cells through membrane projections supported by actin...
... detailing may be an effective implementation model for increasing evidence-based breastcancer screening recommendations among practices in urban areas of higher breastcancer mortality The sampling ... Preventive Oncology, March, 2002 References American Cancer Society: BreastCancer Facts and Figures 2005–2006 Atlanta: American Cancer Society, Inc Centers for Disease Control and Prevention, 2003 National ... information on breastcancer detection was significantly greater in the intervention than in the comparison group at post-test (p = 0.002) Similarly, physician self efficacy in counseling for...